Triplet Regimen Boosts Survival in Metastatic Melanoma, but at a Cost

For patients with metastatic melanoma, triplet therapy with atezolizumab and vemurafenib plus cobimetinib provides significant survival benefits, but the regimen may not be cost-effective, researchers say.
Reuters Health Information
Did you miss our previous article…
https://foreheadthermometers.net/?p=216